نتائج البحث - "David, Vicente"

المصدر: Future Oncology, 17(10), 1165-1184. Future Medicine Ltd.
Garassino, M C, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Ozguroglu, M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Ryden, A, Zhang, Y, O'Brien, C, Dennis, P A & Antonia, S J 2021, ' Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer ', Future Oncology, vol. 17, no. 10, pp. 1165-1184 . https://doi.org/10.2217/fon-2020-1102Test
Garassino, M C, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Özgüroğlu, M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Rydén, A, Zhang, Y, O'Brien, C, Dennis, P A & Antonia, S J 2021, ' Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer ', Future Oncology, vol. 17, no. 10, pp. 1165-1184 . https://doi.org/10.2217/fon-2020-1102Test

مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Durvalumab, durvalumab, Population, Placebo, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Patient Reported Outcome Measures, 030212 general & internal medicine, Stage (cooking), Lung cancer, education, programmed cell death ligand-1, Immune Checkpoint Inhibitors, Neoplasm Staging, Retrospective Studies, education.field_of_study, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Antibodies, Monoclonal, General Medicine, medicine.disease, humanities, Stage III Non-Small Cell Lung Cancer, Clinical trial, Treatment Outcome, patient-reported outcomes, 030220 oncology & carcinogenesis, Female, business, Chemoradiotherapy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8996710d39bff8fe354388b7492bdc5bTest
https://research.vumc.nl/en/publications/c03a6381-5105-41ae-bdc3-fef7664d188bTest

10

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

المؤلفون: Rina Hui, Scott J. Antonia, Catherine Wadsworth, Suresh Senan, Bradford A. Perez, David Vicente, Davey B. Daniel, A. Villegas, Luis Paz-Ares, David R. Spigel, Mustafa Ozguroglu, Shuji Murakami, Corinne Faivre-Finn, Phillip A. Dennis, Helen Broadhurst, Corey J. Langer

المساهمون: Radiation Oncology, CCA - Cancer Treatment and quality of life

المصدر: Faivre-Finn, C, Spigel, D R, Senan, S, Langer, C, Perez, B A, Özgüroğlu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Paz-Ares, L, Broadhurst, H, Wadsworth, C, Dennis, P A & Antonia, S J 2021, ' Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) ', Lung Cancer, vol. 151, pp. 30-38 . https://doi.org/10.1016/j.lungcan.2020.11.024Test
Lung Cancer, 151, 30-38. Elsevier Ireland Ltd
Faivre-finn, C, Spigel, D R, Senan, S, Langer, C, Perez, B A, Özgüroğlu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Paz-ares, L, Broadhurst, H, Wadsworth, C, Dennis, P A & Antonia, S J 2020, ' Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) ', Lung Cancer . https://doi.org/10.1016/j.lungcan.2020.11.024Test

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Randomization, Durvalumab, Lung Neoplasms, Pd-L1 Expression, Docetaxel, Placebo, Vinorelbine, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Median follow-up, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Chemotherapy, Humans, Etoposide, Radiotherapy, business.industry, Antibodies, Monoclonal, Biomarker, Chemoradiotherapy, Concurrent, Carboplatin, Blockade, 030104 developmental biology, Nivolumab, Oncology, chemistry, 030220 oncology & carcinogenesis, Cell Lung-Cancer, Immunotherapy, Cisplatin, business, Non-small-cell lung cancer, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc66d1431e19641df7ad85c29d2fa5d3Test
https://research.vumc.nl/en/publications/a94e824c-5543-4cff-95c7-1dd8269a3f90Test

تنقيح النتائج